Cargando…
Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793326/ https://www.ncbi.nlm.nih.gov/pubmed/36582807 http://dx.doi.org/10.3389/fonc.2022.1113289 |
| _version_ | 1784859832038195200 |
|---|---|
| author | Wang, Sha-Sha Wang, Fang Zeng, Zhen Gao, Fang Liu, Huan-Huan Wang, Hui-Na Hu, Yi Qin, Hai-Feng |
| author_facet | Wang, Sha-Sha Wang, Fang Zeng, Zhen Gao, Fang Liu, Huan-Huan Wang, Hui-Na Hu, Yi Qin, Hai-Feng |
| author_sort | Wang, Sha-Sha |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9793326 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97933262022-12-28 Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient Wang, Sha-Sha Wang, Fang Zeng, Zhen Gao, Fang Liu, Huan-Huan Wang, Hui-Na Hu, Yi Qin, Hai-Feng Front Oncol Oncology Frontiers Media S.A. 2022-12-13 /pmc/articles/PMC9793326/ /pubmed/36582807 http://dx.doi.org/10.3389/fonc.2022.1113289 Text en Copyright © 2022 Wang, Wang, Zeng, Gao, Liu, Wang, Hu and Qin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Oncology Wang, Sha-Sha Wang, Fang Zeng, Zhen Gao, Fang Liu, Huan-Huan Wang, Hui-Na Hu, Yi Qin, Hai-Feng Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_full | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_fullStr | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_full_unstemmed | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_short | Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| title_sort | corrigendum: case report: a novel intergenic mir4299/mir8070-ret fusion with ret amplification and clinical response to pralsetinib in a lung adenocarcinoma patient |
| topic | Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793326/ https://www.ncbi.nlm.nih.gov/pubmed/36582807 http://dx.doi.org/10.3389/fonc.2022.1113289 |
| work_keys_str_mv | AT wangshasha corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT wangfang corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT zengzhen corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT gaofang corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT liuhuanhuan corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT wanghuina corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT huyi corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient AT qinhaifeng corrigendumcasereportanovelintergenicmir4299mir8070retfusionwithretamplificationandclinicalresponsetopralsetinibinalungadenocarcinomapatient |